AnaptysBio, Inc. (AN6.F) Analyst Insights, Price Targets & Recommendations
The article provides an overview of analyst insights, price targets, and recommendations for AnaptysBio, Inc. (AN6.F). It lists recent analyst actions including upgrades, downgrades, and reiterations from firms like JP Morgan, HC Wainwright & Co., Leerink Partners, TD Cowen, and UBS. The stock's current trading information is also displayed, showing a slight gain.
AnaptysBio (NASDAQ:ANAB) Director Sells 5,000 Shares of Company Stock
AnaptysBio (NASDAQ:ANAB) director Hollings Renton sold 5,000 shares of the company's stock for $249,350, reducing his holdings by 31.26%. The sale, executed under a Rule 10b5-1 plan, comes as AnaptysBio reported strong quarterly earnings of $5.11 per share, significantly beating estimates, and revenue of $27.49 million, also exceeding expectations. Despite a "Moderate Buy" consensus rating and an average price target of $77.79 from analysts, the stock is trading near $48.53, well below its 52-week high.
Leerink Partners maintains Outperform rating on AnaptysBio, $81 price target
Leerink Partners has reiterated its Outperform rating on AnaptysBio (ANAB) with an $81 price target, indicating a potential 50.2% upside from its previous close. This positive outlook is driven by AnaptysBio's strong pipeline development, including promising candidates for autoimmune and inflammatory diseases, and favorable market sentiment due to the anticipated resolution of a GSK dispute and Jemperli's sales growth. The company's defined catalyst path with upcoming clinical readouts further enhances investor confidence.
AnaptysBio (ANAB) Flags Positive AZUR 1 Data With Approval And Legal Timelines
AnaptysBio reported positive interim data from its AZUR-1 trial for Jemperli in rectal cancer, outlining regulatory timelines for Jemperli and Quimilza, and new information on ongoing litigation. The company's future revenue visibility hinges on successful execution of regulatory approvals and a clear outcome from its litigation by late 2026/early 2027. This progress supports AnaptysBio's out-licensing model, which relies on partners for drug advancement and commercialization.
Bank of America Corp DE Makes New $28.20 Million Investment in AnaptysBio, Inc. $ANAB
Bank of America Corp DE has made a new $28.20 million investment in AnaptysBio, Inc. (NASDAQ:ANAB), acquiring 417,812 shares, representing a 1.41% stake in the biotechnology company. Other institutional investors like BlackRock also increased their holdings. AnaptysBio has a "Moderate Buy" consensus rating with a target price of $79.85, and recently reported strong Q2 earnings, exceeding revenue and EPS estimates.
AnaptysBio, Inc. (ANAB) Stock Price, News, Quote & History
AnaptysBio, Inc. (ANAB) is a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. The company's stock is currently trading at $50.74, down 5.91%, with a 1-year return of 262.68%. Key products include Rosnilimab, ANB033, and Imsidolimab, with various programs in clinical trials and collaborations with GSK and Vanda.
AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours
AnaptysBio (ANAB) reported a significant swing to profit in its second quarter, achieving $5.11 per diluted share. This positive financial performance, coupled with increased revenue, led to a rise in the company's shares in after-hours trading. The detailed report of their Q2 earnings was released late Monday.
AnaptysBio stock rating maintained at Outperform by Wolfe Research
Wolfe Research has reiterated its Outperform rating on AnaptysBio Inc. (NASDAQ:ANAB) with a $78.00 price target, driven by its analysis of the ongoing litigation between AnaptysBio and GSK concerning contractual obligations related to the drug Jemperli. The firm noted ambiguities in the amendment agreement but suggests AnaptysBio may have a strong case for reversion of rights given Tesaro's alleged failure to meet commercial efforts. Other recent analyst actions include a reduced price target from TD Cowen and new coverage with a Buy rating from H.C. Wainwright.
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? By Investing.com
AnaptysBio Inc. is reporting its second-quarter results, with investor focus on whether Jemperli royalty growth can counteract an anticipated revenue decline. The company's transformation into a royalty-management entity will be scrutinized, as analysts expect a loss of 13 cents per share on $20.2 million in revenue, despite strong analyst ratings and a significant stock surge since its spin-off. Investors will also monitor the outlook for imsidolimab and capital allocation strategies, including a $100 million stock repurchase plan.
Empowered Funds LLC Makes New $13.91 Million Investment in AnaptysBio, Inc. $ANAB
Empowered Funds LLC has made a new $13.91 million investment in AnaptysBio, Inc. (NASDAQ:ANAB), acquiring 206,010 shares during the second quarter, representing about 0.70% of the company. Other institutional investors like Bank of America and HSBC also initiated positions. AnaptysBio shares opened at $56.28, down 1.8%, with analysts maintaining a "Moderate Buy" consensus rating and an average price target of $80.00.
1,844,049 Shares in AnaptysBio, Inc. $ANAB Bought by BlackRock Inc.
BlackRock Inc. has acquired 1,844,049 shares of AnaptysBio, Inc. (NASDAQ:ANAB) in the second quarter, representing a 6.23% ownership stake valued at approximately $124.5 million. AnaptysBio, a clinical-stage biotechnology company, has a market capitalization of $1.67 billion and its shares opened at $56.28. Despite some recent analyst downgrades, the stock maintains a "Moderate Buy" consensus rating with an average price target of $80.00.
Palo Alto Investors LP Purchases Shares of 603,489 AnaptysBio, Inc. $ANAB
Palo Alto Investors LP has acquired 603,489 shares of AnaptysBio, Inc. (NASDAQ:ANAB) during the second quarter, a stake valued at approximately $40.7 million, making it their fifth largest position. This acquisition represents about 2.04% of the biotechnology company, which focuses on developing therapeutic antibody product candidates. Despite a "Moderate Buy" consensus rating and an average price target of $80 from analysts, the stock traded at $56.28 with a market capitalization of $1.67 billion.
Hsbc Holdings PLC Purchases Shares of 216,949 AnaptysBio, Inc. $ANAB
Hsbc Holdings PLC recently acquired 216,949 shares of AnaptysBio, Inc. (NASDAQ:ANAB) in the second quarter, a new position valued at approximately $14.9 million, representing 0.73% of the company. Other institutional investors like JPMorgan Chase, AQR Capital, Creative Planning, Russell Investments, and Arrowstreet Capital also increased their holdings. AnaptysBio, a clinical-stage biotechnology company, currently holds a "Moderate Buy" consensus rating from analysts, with a target price of $80.00, despite a negative price-to-earnings ratio.
Connor Clark & Lunn Investment Management Ltd. Takes Position in AnaptysBio, Inc. $ANAB
Connor Clark & Lunn Investment Management Ltd. has taken a significant new position in AnaptysBio, Inc. (NASDAQ:ANAB), purchasing 141,026 shares valued at approximately $9.5 million during the second quarter. This move is part of broader institutional interest, with several other hedge funds, including BlackRock Inc., also acquiring stakes in the biotechnology company. Analyst sentiment for AnaptysBio remains largely positive, with a "Moderate Buy" consensus and an average price target of $80.00, significantly higher than the stock's current price.
Deutsche Bank AG Makes New Investment in AnaptysBio, Inc. $ANAB
Deutsche Bank AG initiated a new investment in AnaptysBio, Inc. (NASDAQ:ANAB) during the second quarter, purchasing 46,884 shares valued at approximately $3.17 million. Other institutional investors like Vanguard and State Street also increased their holdings. AnaptysBio holds a "Moderate Buy" consensus from analysts with an average price target of $80.
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $70
TD Cowen has reiterated its Buy rating for AnaptysBio (ANAB.US) but has adjusted its price target downwards to $70. This revision indicates a maintained positive outlook on the company's stock despite a lower valuation projection.
ANAB Reiterates Buy by HC Wainwright & Co. -- Price Target Maintained at $95
HC Wainwright & Co. has reiterated a Buy rating for AnaptysBio (ANAB) with a maintained price target of $95.00, reflecting confidence in its growth potential despite its current GF Score™ of 40. The company, which focuses on developing innovative antibody therapies, has a market cap of $1.69 billion and active clinical trials. While analysts see significant upside, the stock's current valuation metrics suggest it may be overvalued relative to historical performance, warranting careful consideration from investors.
AnaptysBio (NASDAQ:ANAB) Given Buy Rating at HC Wainwright
HC Wainwright has reiterated its "Buy" rating for AnaptysBio (NASDAQ:ANAB) and set a price target of $95, indicating a potential upside of 66.7% from its current price. While the stock fell 1.3% in mid-day trading, analyst sentiment remains largely positive with a "Moderate Buy" consensus rating and an average price target of $82, with several institutional investors recently increasing their stakes. Other analysts have also adjusted their ratings and price targets, contributing to the overall positive outlook despite some downgrades.
Bank of America Corp DE Boosts Stock Position in AnaptysBio, Inc. $ANAB
Bank of America Corp DE significantly increased its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 283.2% in the first quarter, acquiring 370,319 additional shares. The firm now holds 501,086 shares valued at approximately $27.8 million, representing 1.72% of the company. Other institutional investors, including Affinity Asset Advisors and Royal Bank of Canada, also boosted their positions, while analysts maintain a "Moderate Buy" consensus rating for AnaptysBio with an average price target of $82.00.
Sirenia Capital discloses 5.0% AnaptysBio (ANAB) ownership in Schedule 13G/A
Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 5.0% in AnaptysBio, Inc. (ANAB) common stock, as detailed in a Schedule 13G/A filing. This stake amounts to 1,491,959 shares, based on 29,608,481 shares outstanding as of June 22, 2026. The shares are held in a managed account of Point72 Associates II, LLC, with Sirenia and Mr. Silverstein exercising shared voting and dispositive power.
Is AnaptysBio (ANAB) Undervalued After Its Recent Share Price Swings?
AnaptysBio (ANAB) has experienced significant share price swings but is considered undervalued by analysts and intrinsic value estimates, trading at a discount despite strong longer-term momentum. The company, focused on immunology therapeutics, is projected to have a fair value of $90 due to rising royalty streams, a future revenue doubling from a loan expiration, and potential upside from a lawsuit. However, investors are cautioned to consider risks like the outcome of GSK litigation and potential deviations in royalty and clinical expectations.
AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility? By Investing.com
AnaptysBio, now operating as Anaptys, is set to release its Q2 earnings, marking its first full quarter as a pure-play royalty management company after spinning off its drug development operations. Analysts predict a loss of 13 cents per share on $20.2 million in revenue, a significant improvement in losses but a revenue decline from the previous quarter. Investors will closely watch Jemperli royalty revenue trajectory and operating margin execution to see if the simplified model can deliver promised profitability and stability despite wavering analyst confidence and potential quarterly volatility.
AnaptysBio (ANAB) awards CEO 53,334 performance stock units
AnaptysBio (ANAB) has awarded its President and CEO, Daniel Faga, 53,334 performance stock units (PSUs). These PSUs were granted after meeting specific performance criteria and will vest over two years, with 50% vesting on March 12, 2027, and the remaining 50% on March 12, 2028, contingent on his continued employment. Each PSU represents one share of common stock.
AnaptysBio (NASDAQ: ANAB) awards 16,667 performance stock units to its CMO
AnaptysBio (NASDAQ: ANAB) has awarded 16,667 performance stock units (PSUs) to its Chief Medical Officer, Paul F. Lizzul. These PSUs were granted on March 12, 2026, after achieving certified performance criteria, with each unit representing a right to one share of common stock. The units will vest 50% on March 12, 2027, and 50% on March 12, 2028, contingent on Lizzul's continued employment.
AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility?
AnaptysBio, now operating as Anaptys, is set to report its Q2 results as a pure-play royalty management company after spinning off its drug development operations. Analysts project a loss of 13 cents per share on $20.2 million in revenue, with a significant improvement in EPS despite an expected revenue decline. Investors will focus on Jemperli royalty revenue trajectory, operating margin execution, and potential variability in royalty recognition.
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of "Moderate Buy" from Brokerages
AnaptysBio, Inc. (NASDAQ:ANAB) has received an average "Moderate Buy" rating from twelve brokerages, with an average 12-month price target of $82.00. Despite missing quarterly earnings per share estimates, the company exceeded revenue expectations. Several institutions have recently increased their holdings in AnaptysBio stock.
AnaptysBio Enters Key Post-Trial Phase in Tesaro Dispute
AnaptysBio (ANAB) has entered a key post-trial phase in its legal dispute with Tesaro and GlaxoSmithKline, involving allegations of material breach of contract and tortious interference. Following a trial in July 2026, a schedule for post-trial briefing and argument has been set, with key dates extending through October 2026 for final arguments. Analysts currently rate ANAB with a "Buy" and a $75.00 price target, though TipRanks' AI Analyst, Spark, notes a "Neutral" outlook due to financial risks despite operational improvements.
AnaptysBio and Tesaro set post-trial briefing schedule after July 2026 trial
AnaptysBio announced the post-trial briefing schedule following its July 2026 litigation with Tesaro and GlaxoSmithKline. A Joint Stipulation was granted by the Court, setting deadlines for briefs, with AnaptysBio filing its opening brief by August 21, 2026. Oral arguments are scheduled for October 20, 2026, moving the case towards a final court decision.
AnaptysBio Inc (ANAB) Financial Health: Profitability & Balance Sheet Analysis
AnaptysBio Inc (ANAB) has a strong financial score of 7.86, placing it high within the Biotechnology & Medical Research industry, indicating robust financial health and high operating efficiency. Despite this, its latest quarterly revenue and net profit experienced year-over-year decreases of 7.98% and 34.47% respectively. The analysis also covers various aspects of its financial performance like Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns.
AnaptysBio-Tesaro trial heads to post-trial briefs, argument set for Oct. 20
AnaptysBio has announced the dates for post-trial briefings in its Delaware Chancery Court dispute with Tesaro and GlaxoSmithKline regarding a collaboration license. AnaptysBio is seeking a declaration that Tesaro materially breached the agreement and alleges GlaxoSmithKline tortiously interfered. The consolidated trial concluded in July 2026, with post-trial arguments scheduled for October 20, 2026.
Arrowstreet Capital Limited Partnership Sells 67,624 Shares of AnaptysBio, Inc. $ANAB
Arrowstreet Capital Limited Partnership reduced its stake in AnaptysBio, Inc. by 12.1% in the first quarter, selling 67,624 shares and retaining 492,120 shares valued at approximately $27.3 million. AnaptysBio reported a significant quarterly loss per share of $1.84, missing analyst expectations, despite revenue exceeding estimates. The company currently has a "Moderate Buy" consensus rating from analysts with an average price target of $82.
ANAB|AnaptysBio Inc|Price:52.220|Chg%:+0.110
This article provides a comprehensive stock analysis of AnaptysBio Inc (ANAB) by TradingKey, highlighting its strong fundamentals and high growth potential. The company's valuation is considered fair within the Biotechnology & Medical Research industry, and it has received "Buy" ratings from multiple analysts. Despite recent weak market performance, its stock is trending sideways between support and resistance levels, making it suitable for range-bound swing trading.
AnaptysBio Inc (ANAB) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for AnaptysBio Inc (ANAB), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 5.15, ranking 50 out of 384 in its industry, and a beta value of 0.89, indicating it tends to underperform in up markets but decline less in down markets. Key metrics like VaR, maximum drawdown, volatility, return, Sharpe ratio, and liquidity are presented to illustrate the stock's risk profile.
AnaptysBio Inc (ANAB) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of AnaptysBio Inc (ANAB), highlighting its current valuation score of 9.19 within the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -51.12, and indicates that P/B, P/S, and P/CF ratios have not yet been disclosed. The analysis emphasizes that relevant data for these metrics are awaiting disclosure from the company.
AnaptysBio (ANAB) Projected to Post Earnings on Wednesday
AnaptysBio (ANAB) is expected to announce its Q2 2026 earnings before market open on Wednesday, August 5th, with analysts projecting a loss of $0.1252 per share and revenue of $17.3340 million. The company missed earnings estimates in the previous quarter but exceeded revenue forecasts. Despite recent price performance below key moving averages, ANAB holds a consensus “Moderate Buy” rating and an $82 price target from analysts.
AnaptysBio shifts to royalty management, focusing on growing Jemperli royalties from GSK.
AnaptysBio has transitioned into a royalty management company, concentrating on Jemperli, an oncology drug commercialized by GSK, after eliminating R&D expenses. The company aims for a 95% EBIT margin with over $140 million in net cash, anticipating increased Jemperli royalties and benefiting from high-margin streams post-2027. This strategy is supported by positive trial data, potential label expansions for Jemperli, and a $100 million share buyback plan.
Eversept Partners LP Decreases Stock Position in AnaptysBio, Inc. $ANAB
Eversept Partners LP significantly reduced its stake in AnaptysBio, Inc. by 77.6% in the first quarter, selling over 93,000 shares and retaining a smaller position valued at $1.5 million. This move comes despite AnaptysBio reporting revenue that exceeded analyst expectations, though it missed on earnings per share. The company still holds a "Moderate Buy" consensus rating from analysts with an average price target of $82.
AnaptysBio Inc (ANAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of AnaptysBio Inc (ANAB), detailing its current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock is currently trading between resistance at $66.44 and support at $45.24, suitable for range-bound swing trading. Technical indicators show a mixed signal with more sells than buys, while moving averages largely indicate a sell signal.
AnaptysBio Inc (ANAB) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of AnaptysBio Inc's (ANAB) shareholder structure, listing major shareholders by proportion, categorizing shareholders by type, and detailing institutional shareholding data over several quarters. It also includes information on shareholder activity and related ETFs.
ANAB|AnaptysBio Inc|Price:54.586|Chg%:+0.436
AnaptysBio Inc. is a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. The company's lead program, Rosnilimab, is in Phase IIb trials for rheumatoid arthritis and Phase II for ulcerative colitis. Detailed company information, including executives, financials, and institutional shareholdings, are provided, showing a recent increase in institutional investment.
First Light Asset Management LLC Decreases Stock Holdings in AnaptysBio, Inc. $ANAB
First Light Asset Management LLC reduced its stake in AnaptysBio Inc. by 12.5% in the first quarter, selling over 80,000 shares but still maintaining a significant holding. Meanwhile, several other institutional investors, including Affinity Asset Advisors and JPMorgan Chase, substantially increased their positions in the biotechnology company. Despite AnaptysBio missing earnings estimates with a loss of $1.84 per share, analysts maintain a "Moderate Buy" consensus with an average price target of $82.
ANAB Cash Flow Statement
This article provides the quarterly and annual cash flow statements for AnaptysBio Inc (ANAB), detailing operating, investing, and financing cash flows from FY2015Q1 to FY2026Q1. It includes specific figures for net income, capital expenditures, and free cash flow, along with year-over-year changes. The document also offers FAQs explaining key cash flow metrics like operating, investing, financing, and free cash flow, and their relevance to ANAB's financial health.
ANAB|AnaptysBio Inc|Price:54.150|Chg%:-0.760
AnaptysBio Inc. (ANAB) closed at $54.150, down 1.38%, with a high growth potential and sound fundamentals, yet its stock price is expected to trend downwards in the medium term. The company is clinical-stage, specializing in immunology therapeutics, with its lead program Rosnilimab currently in Phase IIb and Phase II trials. Analysts have a "Buy" rating with an average target price of $88.80, indicating a potential 61.72% upside.
Hsbc Holdings PLC Buys New Shares in AnaptysBio, Inc. $ANAB
HSBC Holdings PLC has acquired a new stake in AnaptysBio, Inc., purchasing 125,717 shares valued at approximately $7.1 million, representing about 0.43% of the company. This comes despite AnaptysBio reporting a larger-than-expected quarterly loss, though revenue exceeded estimates. Analysts maintain a "Moderate Buy" rating for the stock, with an average price target of $82, and the company recently authorized a significant share buyback plan.
AnaptysBio, Inc.'s Equity Buyback announced on March 24, 2025 has expired with 3,444,079 shares, representing 11.5% for $68.63 million.
AnaptysBio, Inc.'s equity buyback program, which was announced on March 24, 2025, has concluded. The company repurchased 3,444,079 shares, accounting for 11.5% of its equity, at a total cost of $68.63 million. The plan officially expired on March 31, 2026.
AnaptysBio (NASDAQ:ANAB) Trading Up 5.6% - Here's What Happened
AnaptysBio (NASDAQ:ANAB) stock rose 5.6% on Thursday, trading as high as $55.94 with closing near $55.57, though with trading volume significantly lower than average. Analyst sentiment is mixed, leaning positive, with a consensus "Moderate Buy" rating and a price target of $81.82, despite recent downgrades. The company's recent earnings report showed a miss on EPS but beat revenue estimates, and a $100 million stock repurchase authorization suggests management believes the stock is undervalued.
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95
H.C. Wainwright has reiterated its Buy rating for AnaptysBio (ANAB.US) and maintained its target price at $95. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
High Growth Tech Stocks In The US Market
The U.S. market, despite a recent 1.4% decline, has seen a 17% rise over the past year with an anticipated 18% annual earnings growth. This article identifies top high-growth tech stocks, highlighting companies like Ardelyx, AnaptysBio, and Syndax Pharmaceuticals, which demonstrate strong revenue expansion potential and innovation, particularly in biopharmaceuticals. These companies are poised for significant future growth due to their specialized products and strategic financial maneuvers.
Is AnaptysBio (ANAB) Undervalued Following Its Jemperli Royalty Appeal And GSK Trial?
AnaptysBio (ANAB) is drawing attention due to potential royalty income from the cancer drug Jemperli and an upcoming trial with GSK, contributing to significant long-term share price gains despite recent volatility. With analysts suggesting a fair value of $90 against a current price of $62.51, the stock appears undervalued, largely factoring in a favorable resolution to its royalty dispute or a strong ongoing royalty stream. Investors are advised to consider the company's royalty strength and legal outcomes, while also looking into broader healthcare and undervalued stock opportunities.
Significant Decline for AnaptysBio (ANAB) as Shares Drop Over 10%
AnaptysBio (ANAB) shares fell by 10.8% on July 15, 2026, closing at $55.76, amidst broader market volatility and investor caution in the biotechnology sector. The company, a clinical-stage biotech developing antibody product candidates, has a market capitalization of $1.67 billion and a GF Score of 66/100, indicating moderate long-term return potential despite challenges in profitability and significant insider selling. Investors are advised to monitor clinical trial results and market trends.
